Los Angeles Capital Management LLC Lowers Holdings in Stryker Corporation $SYK

Los Angeles Capital Management LLC lowered its holdings in shares of Stryker Corporation (NYSE:SYK) by 58.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,325 shares of the medical technology company’s stock after selling 95,996 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Stryker were worth $27,427,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SYK. Mid American Wealth Advisory Group Inc. bought a new position in Stryker in the 2nd quarter worth approximately $26,000. Sachetta LLC boosted its position in shares of Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 27 shares during the last quarter. Ridgewood Investments LLC grew its stake in Stryker by 48.4% during the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after acquiring an additional 30 shares in the last quarter. Ransom Advisory Ltd bought a new stake in Stryker in the 1st quarter valued at $37,000. Finally, Solstein Capital LLC purchased a new stake in Stryker in the 2nd quarter worth $43,000. Institutional investors own 77.09% of the company’s stock.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the transaction, the director owned 2,702,108 shares in the company, valued at $954,600,714.24. The trade was a 9.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Viju Menon sold 500 shares of the stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 520,500 shares of company stock valued at $184,803,065 in the last 90 days. Company insiders own 5.90% of the company’s stock.

Stryker Price Performance

Shares of Stryker stock opened at $355.74 on Friday. The stock has a market cap of $136.04 billion, a price-to-earnings ratio of 47.12, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The stock has a 50 day moving average price of $374.63 and a 200-day moving average price of $381.22. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The company had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.Stryker’s revenue was up 10.2% on a year-over-year basis. During the same period last year, the company earned $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on SYK shares. Redburn Partners set a $420.00 price objective on Stryker in a research report on Thursday, September 18th. Rothschild & Co Redburn initiated coverage on Stryker in a report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target for the company. Needham & Company LLC lifted their price objective on Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Weiss Ratings reiterated a “buy (b-)” rating on shares of Stryker in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company raised their target price on shares of Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a report on Friday, August 1st. Fourteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $433.37.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.